SG11202004906QA - Radiolabeling of polypeptides - Google Patents
Radiolabeling of polypeptidesInfo
- Publication number
- SG11202004906QA SG11202004906QA SG11202004906QA SG11202004906QA SG11202004906QA SG 11202004906Q A SG11202004906Q A SG 11202004906QA SG 11202004906Q A SG11202004906Q A SG 11202004906QA SG 11202004906Q A SG11202004906Q A SG 11202004906QA SG 11202004906Q A SG11202004906Q A SG 11202004906QA
- Authority
- SG
- Singapore
- Prior art keywords
- radiolabeling
- polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762599830P | 2017-12-18 | 2017-12-18 | |
PCT/US2018/065913 WO2019125982A1 (en) | 2017-12-18 | 2018-12-17 | Radiolabeling of polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202004906QA true SG11202004906QA (en) | 2020-07-29 |
Family
ID=65003549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202004906QA SG11202004906QA (en) | 2017-12-18 | 2018-12-17 | Radiolabeling of polypeptides |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210017099A1 (en) |
EP (1) | EP3727474A1 (en) |
JP (2) | JP2021506842A (en) |
KR (1) | KR20200100094A (en) |
CN (1) | CN111491670A (en) |
AU (1) | AU2018388467A1 (en) |
BR (1) | BR112020012099A2 (en) |
CA (1) | CA3085465A1 (en) |
EA (1) | EA202091420A1 (en) |
IL (1) | IL275242A (en) |
MX (1) | MX2020006395A (en) |
PH (1) | PH12020550690A1 (en) |
SG (1) | SG11202004906QA (en) |
WO (1) | WO2019125982A1 (en) |
ZA (1) | ZA202004424B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA202092839A1 (en) | 2018-05-24 | 2021-02-12 | Янссен Байотек, Инк. | PSMA LINKING AGENTS AND THEIR APPLICATIONS |
WO2022080481A1 (en) * | 2020-10-16 | 2022-04-21 | 日本メジフィジックス株式会社 | Radioactive complexes of anti-her2 antibody, and radiopharmaceutical |
CN113747944A (en) * | 2019-04-19 | 2021-12-03 | 詹森生物科技公司 | Methods of treating prostate cancer with anti-PSMA/CD 3 antibodies |
PE20220935A1 (en) | 2019-05-10 | 2022-05-31 | Janssen Biotech Inc | MACROCYCLIC CHELATORS AND METHODS OF USE OF THESE |
AU2020319963B2 (en) * | 2019-07-30 | 2023-04-27 | Jfe Engineering Corporation | Method for synthesizing zirconium complex |
JPWO2021075546A1 (en) | 2019-10-18 | 2021-04-22 | ||
EP4092016A4 (en) * | 2020-01-16 | 2024-01-17 | JFE Engineering Corporation | Method for synthesizing zirconium complex |
KR20220154728A (en) | 2020-03-13 | 2022-11-22 | 얀센 바이오테크 인코포레이티드 | Materials and methods for binding SIGLEC-3/CD33 |
JP2023527149A (en) * | 2020-05-19 | 2023-06-27 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Methods, systems and kits for polypeptide processing and analysis |
KR20230011417A (en) | 2020-05-20 | 2023-01-20 | 얀센 바이오테크 인코포레이티드 | Methods for Site-Specific Conjugation of Proteins Comprising a Glycosylated Fc Domain |
WO2022203082A1 (en) * | 2021-03-26 | 2022-09-29 | 日本メジフィジックス株式会社 | Compound, method for producing and method for storing compound, method for producing targeting agent, and composition |
AU2022250323A1 (en) * | 2021-03-31 | 2023-11-09 | Nihon Medi-Physics Co., Ltd. | Radioactive complex of anti-egfr antibody, and radiopharmaceutical |
US20240182586A1 (en) * | 2021-05-11 | 2024-06-06 | Northeastern University | Site-Specific Modification of Glycoproteins Through Transglutaminase-Mediated Conjugation |
WO2023190402A1 (en) * | 2022-03-30 | 2023-10-05 | 日本メジフィジックス株式会社 | Method for producing complex |
WO2024030772A1 (en) * | 2022-08-01 | 2024-02-08 | Portland State University | High relaxivity contrast agents and stereoselective preparation |
WO2024059908A1 (en) * | 2022-09-21 | 2024-03-28 | The University Of Melbourne | Radiolabelled compounds |
WO2024107762A2 (en) * | 2022-11-14 | 2024-05-23 | Aktis Oncology, Inc. | Decreased retention of miniproteins in kidney |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747446A (en) * | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
US20080220448A1 (en) * | 2006-09-01 | 2008-09-11 | Blincko Stuart J | Antigenic protein conjugates and process for preparing same |
EP2454598B1 (en) * | 2009-07-15 | 2017-03-22 | DiaTech Holdings, Inc. | Drug selection for gastric cancer therapy using antibody-based arrays |
US10434197B2 (en) | 2010-07-23 | 2019-10-08 | University Of Delaware | Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes |
WO2012075361A2 (en) * | 2010-12-02 | 2012-06-07 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
CN103764665A (en) * | 2011-06-28 | 2014-04-30 | 怀特黑德生物医学研究所 | Using sortases to install click chemistry handles for protein ligation |
US20150246146A1 (en) * | 2012-10-25 | 2015-09-03 | Life Technologies Corporation | Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins |
WO2015057066A1 (en) * | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
US10556024B2 (en) | 2013-11-13 | 2020-02-11 | Whitehead Institute For Biomedical Research | 18F labeling of proteins using sortases |
CA2949365A1 (en) * | 2014-05-16 | 2015-11-19 | Memorial Sloan Kettering Cancer Center | One-step labeling of antibodies to high specific activity with actinium-225 |
GB201417067D0 (en) * | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
WO2016054277A1 (en) * | 2014-09-30 | 2016-04-07 | University Of Pittsburgh -Of The Commonwealth System Of Higher Education | Cu(i)-catalyzed azide-alkyne cycloadditions (cuaac) ligands and methods for carrying out cu(i)-catalyzed azide- alkyne cycloaddition reactions |
GB201504064D0 (en) * | 2015-03-10 | 2015-04-22 | Accretion Biotechnology Ltd | Method and kits for preparing radionuclide complexes |
JP2019522625A (en) * | 2016-05-02 | 2019-08-15 | ユニバーシティ オブ ピッツバーグ −オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Dimerization strategies and compounds for molecular imaging and / or radioimmunotherapy |
-
2018
- 2018-12-17 EP EP18830649.2A patent/EP3727474A1/en active Pending
- 2018-12-17 CN CN201880081895.2A patent/CN111491670A/en active Pending
- 2018-12-17 WO PCT/US2018/065913 patent/WO2019125982A1/en unknown
- 2018-12-17 AU AU2018388467A patent/AU2018388467A1/en active Pending
- 2018-12-17 KR KR1020207019135A patent/KR20200100094A/en not_active Application Discontinuation
- 2018-12-17 EA EA202091420A patent/EA202091420A1/en unknown
- 2018-12-17 BR BR112020012099-5A patent/BR112020012099A2/en unknown
- 2018-12-17 SG SG11202004906QA patent/SG11202004906QA/en unknown
- 2018-12-17 JP JP2020533250A patent/JP2021506842A/en active Pending
- 2018-12-17 CA CA3085465A patent/CA3085465A1/en active Pending
- 2018-12-17 US US16/955,094 patent/US20210017099A1/en active Pending
- 2018-12-17 MX MX2020006395A patent/MX2020006395A/en unknown
-
2020
- 2020-05-22 PH PH12020550690A patent/PH12020550690A1/en unknown
- 2020-06-09 IL IL275242A patent/IL275242A/en unknown
- 2020-07-17 ZA ZA2020/04424A patent/ZA202004424B/en unknown
-
2023
- 2023-03-22 JP JP2023045468A patent/JP2023078366A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL275242A (en) | 2020-07-30 |
AU2018388467A1 (en) | 2020-06-11 |
CA3085465A1 (en) | 2019-06-27 |
EA202091420A1 (en) | 2020-09-10 |
KR20200100094A (en) | 2020-08-25 |
CN111491670A (en) | 2020-08-04 |
US20210017099A1 (en) | 2021-01-21 |
WO2019125982A1 (en) | 2019-06-27 |
ZA202004424B (en) | 2022-06-29 |
JP2021506842A (en) | 2021-02-22 |
BR112020012099A2 (en) | 2020-11-17 |
JP2023078366A (en) | 2023-06-06 |
EP3727474A1 (en) | 2020-10-28 |
MX2020006395A (en) | 2020-12-03 |
PH12020550690A1 (en) | 2021-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202004424B (en) | Radiolabeling of polypeptides | |
IL262482A (en) | Novel polypeptides | |
GB2596983B (en) | Measurement of edema | |
ZA201802261B (en) | Polypeptides | |
IL255767A (en) | Novel polypeptides | |
GB201706477D0 (en) | Modification of polypeptides | |
HK1250041A1 (en) | Polypeptides | |
AU201614763S (en) | Watchcase | |
GB201611530D0 (en) | Novel polypeptides | |
IL269409A (en) | Combinations of chk1- and wee1 - inhibitors | |
GB201700086D0 (en) | Codec | |
ZA201704366B (en) | Il-17a-binding polypeptides | |
HK1250040A1 (en) | Polypeptides | |
IL265628A (en) | Solid state forms of valbenazine | |
GB201707139D0 (en) | Polypeptides | |
GB201619652D0 (en) | Novel polypeptides | |
GB201602857D0 (en) | Connection of rotatable parts | |
SG11201609739UA (en) | Derivatives of dolaproine-dolaisoleuine peptides | |
GB201713559D0 (en) | Modification of polypeptides | |
GB201622143D0 (en) | Modification of polypeptides | |
GB201721386D0 (en) | Chrondogy of time-wave | |
GB201717958D0 (en) | Novel polypeptides | |
GB201706915D0 (en) | Novel polypeptides | |
GB201708700D0 (en) | Improvements of magflow meters | |
ZAA201601633S (en) | Watch |